Ab's dry (AMD) humor
A collaborative effort by Pfizer Inc. and U.S. academicshas found that immunotherapy against beta-amyloid can reverse the retinal protein deposition that leads to dry age-related macular degeneration. The finding could open up a repurposing opportunity for mAbs in development for Alzheimer's disease.1
"We've established beta-amyloid as a therapeutic target for dry AMD," a thus far untreatable form of the disease, said team leader Catherine Bowes Rickman, associate professor of ophthalmology and cell biology at Duke University.
Bowes Rickman's team built on prior